Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04257617 | A Trial of ZL-1201 in Subjects With Advanced Cancer | PHASE1 | COMPLETED | 37 | — | — | May 11, 2020 | Jan 19, 2023 | Aug 22, 2023 | 7 | United States, China |
Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Single arm, ZL-1201 | EXPERIMENTAL | Single arm, ZL-1201 |
| Name | Type | Description |
|---|---|---|
| ZL-1201 | DRUG | Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2. |
Inclusion Criteria: * Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists. * Adequate hematologic status * Adequate coagulation function ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |